To analyze the long-term outcomes and safety of intravitreal ranibizumab injections in myopic choroidal neovascularization (CNV).
A retrospective non-randomized analysis of consecutive cases included 17 eyes from 17 patients with subfoveal myopic CNV, treated with intravitreal ranibizumab with at least 30-month follow-up. The patients received three injections monthly, followed by pro re nata regimen. Best-corrected visual acuity (BCVA) measurement, optical coherence tomography and fluorescein angiography were carried out at the baseline and at monthly intervals thereafter.
Mean follow-up period was 51 months (range 30–98 months). In 12 patients (70.6%), BCVA improved by at least 1 Snellen line, with at least 3-line improvement observed in the case of 8 eyes (47%). Mean central foveal thickness (CFT) decreased from 384.65 ± 103.3 µm at the baseline to 264 ± 86.2 µm at the last follow-up examination (p < 0.001). The final OCT examination revealed 59% (10/17) eyes with CNV-related macular atrophy. Mean number of injections over the follow-up period was 4.82 ± 2.04 per person. Nine patients (53%) required re-injection of the anti-VEGF agent; the mean number of re-injections in this group was 3.44 ± 1.34 per person (range 2–6). No significant adverse events were recorded during the study period.
Intravitreal ranibizumab is an effective and safe treatment for CNV secondary to pathologic myopia, contributing to long-term vision improvement and CFT reduction.
This is a preview of subscription content, access via your institution.
Buy single article
Instant access to the full article PDF.
Tax calculation will be finalised during checkout.
Subscribe to journal
Immediate online access to all issues from 2019. Subscription will auto renew annually.
Tax calculation will be finalised during checkout.
Yoshida T, Ohno-Matsui K, Yasuzumi K, Kojima A, Shimada N, Futagami S et al (2003) Myopic choroidal neovascularization: a 10-year follow-up. Ophthalmology 110(7):1297–1305
Avila MP, Weiter JJ, Jalkh AE, Trempe CL, Pruett RC, Schepens CL (1984) Natural history of choroidal neovascularization in degenerative myopia. Ophthalmology 91(12):1573–1581
Ohno-Matsui K (2017) What is the fundamental nature of pathologic myopia? Retina 37(6):1043–1048
Grossniklaus HE, Green WR (1992) Pathologic findings in pathologic myopia. Retina 12(2):127–133
Lai TY, Cheung CM (2016) Myopic choroidal neovascularization: diagnosis and treatment. Retina 36(9):1614–1621
Wong TY, Ohno-Matsui K, Leveziel N, Holz FG, Lai TY, Yu HG et al (2015) Myopic choroidal neovascularisation: current concepts and update on clinical management. Br J Ophthalmol 99(3):289–296
Cheung CMG, Arnold JJ, Holz FG, Park KH, Lai TYY, Larsen M et al (2017) Myopic choroidal neovascularization: review, guidance, and consensus statement on management. Ophthalmology 124(11):1690–1711
Wang E, Chen Y (2013) Intravitreal anti-vascular endothelial growth factor for choroidal neovascularization secondary to pathologic myopia: systematic review and meta-analysis. Retina 33(7):1375–1392
Wu TT, Kung YH (2017) Five-year outcomes of intravitreal injection of ranibizumab for the treatment of myopic choroidal neovascularization. Retina 37(11):2056–2061
Lai TY (2012) Anti-vascular endothelial growth factor therapy for myopic choroidal neovascularization: do we need more evidence? Retina 32(8):1443–1445
Wolf S, Balciuniene VJ, Laganovska G, Menchini U, Ohno-Matsui K, Sharma T et al (2014) RADIANCE: a randomized controlled study of ranibizumab in patients with choroidal neovascularization secondary to pathologic myopia. Ophthalmology 121(3):682–692
Kung YH, Wu TT, Huang YH (2014) One-year outcome of two different initial dosing regimens of intravitreal ranibizumab for myopic choroidal neovascularization. Acta Ophthalmol 92(8):e615–e620
Lai TY, Chan WM, Liu DT, Lam DS (2009) Intravitreal ranibizumab for the primary treatment of choroidal neovascularization secondary to pathologic myopia. Retina 29(6):750–756
Wu TT, Kung YH (2012) The 12-month outcome of three consecutive monthly intravitreal injections of ranibizumab for myopic choroidal neovascularization. J Ocul Pharmacol Ther 28(2):129–133
Silva RM, Ruiz-Moreno JM, Rosa P, Carneiro A, Nascimento J, Rito LF et al (2010) Intravitreal ranibizumab for myopic choroidal neovascularization: 12-month results. Retina 30(3):407–412
Tufail A, Narendran N, Patel PJ, Sivaprasad S, Amoaku W, Browning AC et al (2013) Ranibizumab in myopic choroidal neovascularization: the 12-month results from the REPAIR study. Ophthalmology 120(9):1944–1945
Tufail A, Patel PJ, Sivaprasad S, Amoaku W, Browning AC, Cole M et al (2013) Ranibizumab for the treatment of choroidal neovascularisation secondary to pathological myopia: interim analysis of the REPAIR study. Eye (Lond) 27(6):709–715
Lorenzo D, Arias L, Alcubierre R, Pujol O, Caminal JM, Rubio M et al (2011) Intravitreal ranibizumab for choroidal neovascularization secondary to pathological myopia: 12-month follow-up. Ophthalmologica 226(3):103–109
Lai TY, Luk FO, Lee GK, Lam DS (2012) Long-term outcome of intravitreal anti-vascular endothelial growth factor therapy with bevacizumab or ranibizumab as primary treatment for subfoveal myopic choroidal neovascularization. Eye (Lond) 26(7):1004–1011
Franqueira N, Cachulo ML, Pires I, Fonseca P, Marques I, Figueira J et al (2012) Long-term follow-up of myopic choroidal neovascularization treated with ranibizumab. Ophthalmologica 227(1):39–44
Ruiz-Moreno JM, Arias L, Montero JA, Carneiro A, Silva R (2013) Intravitreal anti-VEGF therapy for choroidal neovascularisation secondary to pathological myopia: 4-year outcome. Br J Ophthalmol 97(11):1447–1450
Peiretti E, Vinci M, Fossarello M (2012) Intravitreal bevacizumab as a treatment for choroidal neovascularisation secondary to myopia: 4-year study results. Can J Ophthalmol 47(1):28–33
Gass JDM (1987) Stereoscopic atlas of macular diseases: diagnosis and treatment, 3rd edn. Mosby, St. Louis
Chen Y, Sharma T, Li X, Song Y, Chang Q, Lin R et al (2019) Ranibizumab versus verteporfin photodynamic therapy in Asian patients with myopic choroidal neovascularization: brilliance, a 12-month, randomized, double-masked study. Retina 39(10):1985–1994
Ikuno Y, Ohno-Matsui K, Wong TY, Korobelnik JF, Vitti R, Li T et al (2015) Intravitreal aflibercept injection in patients with myopic choroidal neovascularization: the MYRROR study. Ophthalmology 122(6):1220–1227
El Matri L, Chebil A, Kort F (2015) Current and emerging treatment options for myopic choroidal neovascularization. Clin Ophthalmol 9:733–744
Calvo-Gonzalez C, Reche-Frutos J, Donate J, Fernandez-Perez C, Garcia-Feijoo J (2011) Intravitreal ranibizumab for myopic choroidal neovascularization: factors predictive of visual outcome and need for retreatment. Am J Ophthalmol 151(3):529–534
Mones JM, Amselem L, Serrano A, Garcia M, Hijano M (2009) Intravitreal ranibizumab for choroidal neovascularization secondary to pathologic myopia: 12-month results. Eye (Lond) 23(6):1275–1280 (quiz 81)
Lalloum F, Souied EH, Bastuji-Garin S, Puche N, Querques G, Glacet-Bernard A et al (2010) Intravitreal ranibizumab for choroidal neovascularization complicating pathologic myopia. Retina 30(3):399–406
Hefner L, Gerding H (2017) 6-Year results of CNV secondary to pathological myopia treated with ranibizumab. Klin Monbl Augenheilkd 234(4):483–486
Ruiz-Moreno JM, Montero JA, Araiz J, Arias L, Garcia-Layana A, Carneiro A et al (2015) Intravitreal anti-vascular endothelial growth factor therapy for choroidal neovascularization secondary to pathologic myopia: six years outcome. Retina 35(12):2450–2456
Pastore MR, Capuano V, Bruyere E, Miere A, Corbelli E, Querques L et al (2018) Nine-year outcome of ranibizumab monotherapy for choroidal neovascularization secondary to pathologic myopia. Ophthalmologica 239(2–3):133–142
Kasahara K, Moriyama M, Morohoshi K, Yoshida T, Simada N, Nagaoka N et al (2017) Six-year outcomes of intravitreal bevacizumab for choroidal neovascularization in patients with pathologic myopia. Retina 37(6):1055–1064
Ventrice P, Leporini C, Aloe JF, Greco E, Leuzzi G, Marrazzo G et al (2013) Anti-vascular endothelial growth factor drugs safety and efficacy in ophthalmic diseases. J Pharmacol Pharmacother 4(Suppl 1):S38–S42
Zhu H, Wang FH, Sun XD (2013) Anti-vascular endothelial growth factor: the future treatment of choroidal neovascularization in pathologic myopia? Chin Med J (Engl) 126(8):1578–1583
Hashemi S, Faramarzi MA, Ghasemi Falavarjani K, Abdollahi M (2014) Bevacizumab for choroidal neovascularization secondary to age-related macular degeneration and pathological myopia. Expert Opin Biol Ther 14(12):1837–1848
This research did not receive any specific grant from funding agencies in the public, commercial or not-for-profit sectors.
Conflict of interest
The authors declare that they have no conflict of interest.
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
About this article
Cite this article
Wasiluk, E., Wojnar, M., Obuchowska, I. et al. Long-term outcomes of the intravitreal injection of ranibizumab for the treatment of choroidal neovascularization secondary to pathologic myopia. Int Ophthalmol 40, 833–839 (2020). https://doi.org/10.1007/s10792-019-01247-w
- Myopic CNV
- Intravitreal anti-VEGF
- Pathologic myopia